Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow XLO by emailGet an email when XLO pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about XLO, unsubscribe in one click. Privacy
📣 What XLO Says Is Next
first half of 2027 · “Xilio is evaluating efarindodekin alfa as a monotherapy in an ongoing Phase 2 clinical trial in patients with advanced solid tumors and expects to deliver an option data package to Gilead Sciences, Inc. (Gilead) in the first half of 2027.”
Company press release, Aug 12, 2026 · SEC filing
second half of 2027 · “Xilio plans to submit INDs for its CLDN18.2 and PSMA+STEAP1 programs in the second half of 2027.”
Company press release, Aug 12, 2026 · SEC filing
second half of 2027 · “Xilio plans to report initial Phase 1 data in patients with metastatic NSCLC in the second half of 2027.”
Company press release, Aug 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full XLO picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for XLO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.